An advisory panel recommended that hydrocodone be more restricted . Panel : hydrocodone , a Schedule III drug , should be under more restrictive Schedule III . The FDA could limit how much hydrocodone a patient could get between doctor visits . The FDA has not said when it would act on the recommendation .
An advisory panel recommends that hydrocodone be more restricted . Panel : hydrocodone , a Schedule III drug , should be under more restrictive Schedule II . The FDA could limit how much hydrocodone a patient could get between doctor visits . The FDA has not said when it would act on the recommendation .